Keywords: Amirall, Forest Labs, Aclidinium, Research, COPD, Bystolic, CHF, FDA

Almirall rises on positive Ph III results for aclidinium in COPD, partnered with Forest; Likely FDA “no” to Forests’ Bystolic in CHF

Article | 08 January 2010

Print This

Spain’s largest drugmaker Almirall saw its share price rise 3.9% to 9.51 euros in morning trading yesterday when - together with ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in